Europe’s medicines watchdog on Friday rejected a marketing request for a new Alzheimer’s disease treatment, saying the risks of the medicine’s side effects, including potential brain bleeding, outweighed the benefits.
Medical Xpress – latest medical and health news stories
Discover more from Nurse Unity Chats
Subscribe to get the latest posts sent to your email.
